

IFW

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 4, 2005

Date

Miyabi Grace

Miyabi Grace

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	10/763,450	Group Art Unit:	1646
Applicant(s):	Mary Mah Lee Ng; Justin Jang Hann Chu	Examiner:	To be assigned
Filing Date:	January 22, 2004	Docket No.	59419-010101
Title:	MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUS	Customer No.	33717

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
[37 C.F.R. § 1.56]

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

This Information Disclosure Statement is being submitted within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office action on the merits, and therefore, Applicant believes no fee is required;


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is believed due with the submission of this paper. However, if the Applicants are mistaken, the Director is authorized to charge any required fee(s) or any underpayment of fee(s), or to credit any overpayments to Deposit Account Number 50-2638, Deposit Account Name Greenberg Traurig, LLP. Please ensure that the Attorney Docket Number is referred to when charging any payments or credits for this case.


Respectfully submitted,

GREENBERG TRAURIG, LLP

Date February 4, 2005

By 
Claude Nassif, Ph.D.
Reg. No. 52,061
Tel.: (310) 586-7828

Greenberg Traurig, LLP
2450 Colorado Avenue, Suite 400
Santa Monica, California 90404
Telephone: 310-586-7700
Facsimile: 310-586-7800



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)**Complete if Known**

Application Number	10/763,450
Filing Date	January 22, 2004
First Named Inventor	Mary NG Mah Lee
Art Unit	1646
Examiner Name	To be assigned
Attorney Docket Number	59419-010101

Sheet	1	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Castle <i>et al</i> ; Nucleotide sequence of the 5'-terminal untranslated part of the genome of the flavivirus West Nile virus; Arch Virol; Vol. 92; 1987; pp. 309-313.	
		Cole <i>et al</i> ; The EBV-Hybridoma Technique and Its Application to Human Lung Cancer; Monoclonal Antibodies And Cancer Therapy; Alen R. Liss, Inc.; 1985; pp. 77-96	
		Cote <i>et al</i> ; Generation of human monoclonal antibodies reactive with cellular antigens; Proc. Natl Acad. Sci. USA; Vol. 80; April 1983; pp. 2026-2030.	
		De Madrid <i>et al</i> ; The flaviviruses (group B arboviruses): a cross-neutralization study; J Gen Virol; Vol. 23; 1974; pp. 91-96.	
		George <i>et al</i> ; Isolation of West Nile virus from the brains of children who had died of encephalitis; Bull World Health Organ; Vol. 62, No. 6; 1984; pp. 879-882.	
		Gollins <i>et al</i> ; Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry; J Gen Virol; Vol. 66; 1985; pp. 1969-1982.	
		Hase <i>et al</i> ; A comparative study of entry modes into C 6/36 cells by Semliki Forest and Japanese encephalitis viruses; Archives of Virology; Vol. 108; 1989; pp. 101-114	
		Hase <i>et al</i> ; Entry and replication of Japanese encephalitis virus in cultured neurogenic cells; J Virol Methods; Vol. 30; 1990; pp. 205-214.	
		Hase <i>et al</i> ; Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes; Arch Virol; Vol. 104; 1989; pp. 129-143.	
		Hase <i>et al</i> ; Morphogenesis of flaviviruses; Subcell Biochem; Vol. 15; 1989; pp. 275-305.	
		Heinz <i>et al</i> ; The interactions of the flavivirus envelope proteins: implications for virus entry and release; Arch Virol Suppl; Vol. 9, Suppl; 1994; pp. 339-348.	
		Köhler <i>et al</i> ; Continuous cultures of fused cells secreting antibody of predefined specificity; Nature; Vol. 256; Aug 7, 1975; pp. 495-497.	
		Kopecký <i>et al</i> ; A putative host cell receptor for tick-borne encephalitis virus identified by anti-idiotypic antibodies and virus affino blotting; Intervirology; Vol. 42; 1999; pp. 9-16.	
		Kozbor <i>et al</i> ; The production of monoclonal antibodies from human lymphocytes; Immunology Today; 1983; Vol. 4, No. 3; pp. 72-79.	

LA-FS1\317728v01\59419.010101

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,450
				Filing Date	January 22, 2004
				First Named Inventor	Mary NG Mah Lee
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	59419-010101

NON PATENT LITERATURE DOCUMENTS			
		Ramos-Castaneda <i>et al</i> ; A 65-kDa trypsin-sensible membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells; J Neurovirol; Vol. 3; 1997; pp. 435-440.	
		Rey <i>et al</i> ; The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution; Nature; Vol. 375; May 25, 1995; pp. 291-298.	
		Rice; <i>Flaviviridae</i> : the viruses and their replication; Fields Virology, Third Edition; Fields, <i>et al</i> editors; Lippincott-Raven; Philadelphia, PA.; Chapter 30; pp. 931-959.	
		Shi <i>et al</i> ; Actions of neurotensin: a review of the electrophysiological studies; Ann NY Acad. Sci.; Vol. 668; 1992; 1129-145.	
		Tokuyasu; Immuno-cryoultramicrotomy; Immunolabelling for Electron Microscopy; Polak <i>et al</i> . editors; Amsterdam; Elsevier Science; Chapter 6; pp. 71-82.	
		Wengler <i>et al</i> ; Sequence analysis of the membrane protein V3 of the flavivirus West Nile virus and of its gene; Virology; Vol. 147; 1985; pp. 264-274.	
		Wengler <i>et al</i> ; Studies on virus-specific nucleic acids synthesized in vertebrate and mosquito cells infected with flaviviruses; Virology; Vol. 89; 1978; pp. 423-437.	

LA-FS1317728v01\59419.010101

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.